Literature DB >> 9288696

A study of European womens' experience of the problems of urogenital ageing and its management.

D H Barlow1, G Samsioe, J M van Geelen.   

Abstract

OBJECTIVES: A six country Pan-European study of aspects of urogenital ageing (UGA).
METHODS: The study was carried out using a stratified random sample of 3000 women between the ages of 55 and 75 years.
RESULTS: A total of 30% suffered from UGA symptoms, of whom 60% made efforts to alleviate their UGA problems, most commonly using HRT. There were some international differences regarding womens' perceptions of HRT, sexual relationships, prevalence and treatment of UGA problems and their attitudes to them across the six European States.
CONCLUSIONS: Despite some international differences there was a generally similar experience of UGA problems across the six European populations studied, with a minority of women suffering significantly, however the distress of that subgroup highlighted the need for health professionals to appreciate the impact of UGA on those affected and to understand that many of these older women may be reticent in seeking help.

Entities:  

Mesh:

Year:  1997        PMID: 9288696     DOI: 10.1016/s0378-5122(97)00047-9

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  10 in total

Review 1.  Effect of SERMs on the uterus and menopausal symptoms.

Authors:  M Dören
Journal:  J Endocrinol Invest       Date:  1999-09       Impact factor: 4.256

2.  Over-the-counter treatments and perineal hygiene in postmenopausal women.

Authors:  Elisabeth A Erekson; Deanna K Martin; E Christine Brousseau; Sallis O Yip; Terri R Fried
Journal:  Menopause       Date:  2014-03       Impact factor: 2.953

Review 3.  A review of the impact of pregnancy and childbirth on pelvic floor function as assessed by objective measurement techniques.

Authors:  Hans Van Geelen; Donald Ostergard; Peter Sand
Journal:  Int Urogynecol J       Date:  2018-01-13       Impact factor: 2.894

4.  Local Effects of Vaginally Administered Estrogen Therapy: A Review.

Authors:  Megan Krause; Thomas L Wheeler; Thomas E Snyder; Holly E Richter
Journal:  J Pelvic Med Surg       Date:  2009-05

5.  The Vulvovaginal Symptoms Questionnaire: a questionnaire for measuring vulvovaginal symptoms in postmenopausal women.

Authors:  Elisabeth A Erekson; Sallis O Yip; Terri S Wedderburn; Deanna K Martin; Fang-Yong Li; Jennifer N Choi; Kimberly S Kenton; Terri R Fried
Journal:  Menopause       Date:  2013-09       Impact factor: 2.953

Review 6.  Dyspareunia in postmenopausal women: a critical review.

Authors:  A Kao; Y M Binik; A Kapuscinski; S Khalife
Journal:  Pain Res Manag       Date:  2008 May-Jun       Impact factor: 3.037

7.  Urogynecology in obstetrics: impact of pregnancy and delivery on pelvic floor disorders, a prospective longitudinal observational pilot study.

Authors:  Russalina Stroeder; Julia Radosa; Lea Clemens; Christoph Gerlinger; Gilda Schmidt; Panagiotis Sklavounos; Zoltan Takacs; Gabriele Meyberg-Solomayer; Erich-Franz Solomayer; Amr Hamza
Journal:  Arch Gynecol Obstet       Date:  2021-03-22       Impact factor: 2.344

8.  Consistency of Effect with a Low-Dose, Estradiol Vaginal Capsule (TX-004HR): Evaluating Improvement in Vaginal Physiology and Moderate-to-Severe Dyspareunia in Subgroups of Postmenopausal Women.

Authors:  Ginger D Constantine; Celine Bouchard; James H Pickar; David F Archer; Shelli Graham; Brian Bernick; Sebastian Mirkin
Journal:  J Womens Health (Larchmt)       Date:  2017-03-29       Impact factor: 2.681

9.  Longitudinal Study of Pelvic Floor Characteristics Before, During, and After Pregnancy in Nulliparous Women.

Authors:  Ioana-Claudia Lakovschek; Gerda Trutnovsky; Barbara Obermayer-Pietsch; Daniela Gold
Journal:  J Ultrasound Med       Date:  2021-03-07       Impact factor: 2.754

10.  Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy.

Authors:  S R Goldstein; G A Bachmann; P R Koninckx; V H Lin; D J Portman; O Ylikorkala
Journal:  Climacteric       Date:  2013-11-23       Impact factor: 3.005

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.